» Articles » PMID: 20551469

Targeted Treatments in Colorectal Cancer: State of the Art and Future Perspectives

Overview
Journal Gut
Specialty Gastroenterology
Date 2010 Jun 17
PMID 20551469
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Targeted treatments have generated a lot of hope and hype in the treatment of gastrointestinal tumours. Indeed, the introduction of targeted treatments particularly for colorectal cancer has resulted in substantial improvements in tumour response and progression-free survival of patients. However, it is not fully understood how these agents act in patients, and the preclinical models are not appropriate to predict clinical efficacy. Here the current state of targeted treatments in colorectal cancer is reviewed, focusing on antiepidermal growth factor receptor (EGFR) and antiangiogenic strategies, describing how these agents fit into the therapeutic algorithm of this disease and discussing current understanding of the mechanism of action, biomarkers as well as future therapeutic strategies targeting multiple signalling pathways in colorectal cancer.

Citing Articles

Glucagon Enhances Chemotherapy Efficacy By Inhibition of Tumor Vessels in Colorectal Cancer.

Xu Y, Ni F, Sun D, Peng Y, Zhao Y, Wu X Adv Sci (Weinh). 2023; 11(6):e2307271.

PMID: 38072640 PMC: 10853751. DOI: 10.1002/advs.202307271.


Successful multidisciplinary therapy for a patient with liver metastasis from ascending colon adenocarcinoma: A case report and review of literature.

Tan X, Li J, Chen H, Luo W, Jiang N, Wang Z World J Clin Cases. 2023; 11(7):1498-1505.

PMID: 36926405 PMC: 10011996. DOI: 10.12998/wjcc.v11.i7.1498.


HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with Wild Type Metastatic Colorectal Cancer.

Khelwatty S, Puvanenthiran S, Essapen S, Bagwan I, Seddon A, Modjtahedi H Cancers (Basel). 2021; 13(4).

PMID: 33562755 PMC: 7914886. DOI: 10.3390/cancers13040638.


The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).

Bendell J, Sauri T, Gracian A, Alvarez R, Lopez-Lopez C, Garcia-Alfonso P Oncologist. 2020; 25(3):e451-e459.

PMID: 32162804 PMC: 7066709. DOI: 10.1634/theoncologist.2019-0291.


Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.

Hendricks A, Rosenstiel P, Hinz S, Burmeister G, Rocken C, Boersch K BMC Med Genet. 2020; 21(1):3.

PMID: 31900123 PMC: 6942307. DOI: 10.1186/s12881-019-0941-5.